CORE--MICRODISSECTION

核心——显微切割

• 批准号: 6334937
• 负责人: D CRAIG ALLRED
• 金额: $ 18.15万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-08-01 至 2001-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6334937
• 关键词: biomedical facility; breast neoplasms; dissection; gene expression; histology; human tissue; polymerase chain reaction; single strand conformation polymorphism

Our program Project is dedicated to studying human breast cancer in vivo. This often means that biological studies are performed directly on clinical specimens. This can be problematic when assessing the structure and expression of genes, in that clinical specimens are nearly always composed of complex mixtures of normal cells and tumor cells. The results of the extremely sensitive molecular techniques we use to analyze DNA and RNA are uninterpretable unless their substrate is prepared from a highly purified sample of one cell type. Thus, target cells must be separated from non-target cells before the samples are prepared, and we do this by manually microdissecting histological tissue sections on glass slides. Several of these molecular techniques (e.g. allelic imbalance, single-strand conformational polymorphism, differential display, and reverse-transcriptase PCR) are being used by three projects in this Program Project (projects 3, 4, and 5). The samples supporting these studies will come from the Evolutionary Tissue Bank in the Tumor Bank and Data Network Core, and the slides will be prepared in the Histology and Immunohistochemistry Core. They will be microdissected in this Core.

我们的计划项目致力于研究人类乳腺癌 体内。 这通常意味着直接进行生物学研究 在临床标本上。 评估时，这可能是有问题的 基因的结构和表达，该临床标本几乎是 始终由正常细胞和肿瘤细胞的复杂混合物组成。 我们使用的极灵敏分子技术的结果 分析DNA和RNA是无法解释的，除非它们的底物为 从一种细胞类型的高度纯化样品中制备。 因此，目标 在样品为之前，必须将细胞与非目标细胞分离 准备好，我们通过手动微型解散组织学来做到这一点 载玻片上的组织切片。 其中几种分子技术 （例如，等位基因失衡，单链构象多态性， 差分显示和反向转录酶PCR）正在使用 该计划项目中的三个项目（项目3、4和5）。 这 支持这些研究的样本将来自进化 肿瘤库和数据网络核心的组织库，以及 幻灯片将在组织学和免疫组织化学中制备 核。 它们将在此核心中进行微解码。